secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001104659-23-116370
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin reports positive Phase 2 data for QRX003 in Netherton Syndrome; cash $14M
-------------------------------------------------------------------------------

- Five of six evaluable subjects showed negligible/absent pruritus after QRX003 treatment in open-label study.
- All six subjects improved in Investigator skin scoring; favorable patient global assessment across metrics.
- No safety concerns in either ongoing study; protocol amendments planned: eliminate lower 2% dose, twice-daily dosing.
- Cash, equivalents and marketable securities $14.0M as of Sept 30, 2023; runway expected through end of 2024.
- Net loss $2.1M for Q3 2023 vs $2.3M for Q3 2022; nine-month net loss $7.2M flat year-over-year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465923116370/0001104659-23-116370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465923116370/tm2330370d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer